Huntington’s disease (HD) is caused by an expansion of a short DNA sequence — the letters C-A-G — located in the very first ...

In people with premanifest HD, lower scores on the visual thinking tests were linked with more movement changes over time.

A new Phase 1 study is testing SRP-1005, a huntingtin-lowering therapy given by injection under the skin. It’s early days, but this approach could add an important new arrow to the HD drug development ...

August has been a packed month for Huntington’s disease (HD) research. We’ve looked at what can be learned from disappointing ...

First to speak was Aikaterini Papadopoulou, who talked about her work targeting a fragment of the expanded HTTHTT one abbreviation for the gene that causes Huntington’s disease. The same gene is also ...

Long-time HDBuzz readers may recognise pridopidine. Pridopidine has had one of the longest and most winding development journeys of any experimental HD therapy. Originally developed as a treatment for ...

This morning kicks off with talks focussed on HD genetics and how DNA repair machines influence how symptoms start and then progress in people with HD. The first speaker was Vanessa Wheeler, whose ...

A new study from researchers at the University of Washington and University College London explores different ways to lower the huntingtin proteinhuntingtin protein The protein produced by the HD gene ...

We’re pleased to announce the 2026 HDBuzz Prize! This year, the HDBuzz Prize is brought to you by the Huntington’s Disease Foundation (HDF), who are sponsoring this year’s competition. Training the ...

In plain language. Written by scientists. A new Phase 1 study is testing SRP-1005, a huntingtin-lowering therapy given by injection under the skin. It’s early days, but this approach could add an ...

In plain language. Written by scientists. Day 3 of #HD2026 put HTT under the microscope. Researchers shared new insights into HTT1a, next-generation HTT-lowering approaches, somatic expansion, brain ...